Q1 2023 RevenueQuarterly activity

See original here:
Guerbet: Q1 2023 Revenue

VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the presentation of new data describing the progress of the Company’s kt-3000 drug development program at the American Association of Cancer Research (AACR) annual meeting in Orlando, Florida.

Go here to see the original:
Rakovina Therapeutics Announces Presentation of New kt-3000 Series Data at AACR Annual Meeting

- Presentations to cover updated clinical and preclinical data on pipeline candidates in Company’s thyroid eye disease program -

Originally posted here:
UPDATE – Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology

GÉNOMIQUE | THÉRAPIES CELLULAIRES & GÉNÉTIQUES | BIOPRODUCTION

Continued here:
Génomique | Thérapies Cellulaires & Génétiques | Bioproduction - RÉSULTATS ANNUELS 2022

REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the first quarter of 2023 after market close on Tuesday, May 9, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Go here to see the original:
Seer to Report First Quarter 2023 Financial Results on May 9, 2023

SHANGHAI, China, April 20, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that positive interim event-free survival (EFS) results from the Neotorch study were presented at the ASCO April Plenary Series.

View post:
Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative...

FREMONT, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2023 after market close on Tuesday, May 9th, 2023. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.

Go here to see the original:
Cytek Biosciences to Report First Quarter 2023 Financial Results on May 9, 2023

CUPERTINO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting a poster at the 78th Annual Scientific Convention of the Society of Biological Psychiatry, to be held in San Diego, CA April 27-29, 2023.

Go here to see the original:
Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual Scientific Convention of the Society of...

SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Timothy Moore to Executive Vice President, Chief Technical Officer effective April 24, 2023. The selection of Mr. Moore, the former Executive Vice President, Technical Operations of Kite Pharma responsible for the global development of two of the most commercially successful autologous CAR T manufacturing processes in the industry, reinforces the Company’s mission to being the first to bring an AlloCAR T product to market. Mr. Moore succeeds Alison Moore, Ph.D., who intends to serve as a consultant to Allogene.

View original post here:
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer

WINNIPEG, Manitoba, April 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), today announced its fourth quarter and full year 2022 financial results.

Read more here:
Kane Biotech Announces Fourth Quarter and Full Year 2022 Financial Results

REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of market. The Company will not be conducting a conference call in conjunction with this financial results release.

Read more:
Codexis to Report First Quarter 2023 Financial Results on May 4

Plus completes Phase 1/Part A of the ReSPECT-LM trial

Here is the original post:
Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Steve Rusckowski has joined Supervisory Board and will stand for election at Annual General Meeting in June 2023 Steve Rusckowski has joined Supervisory Board and will stand for election at Annual General Meeting in June 2023

More here:
QIAGEN announces expansion of Supervisory Board

MONMOUTH JUNCTION, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, presented positive initial safety data from Phase 1 dose escalation trial of ELU001 (NCT05001282) in a poster titled “ELU-FR?-1: A Study to Evaluate ELU001, a C’Dot Drug Conjugate, in Patients with Solid Tumors that Overexpress Folate Receptor Alpha (FR?)” (abstract #CT255) at the American Association for Cancer Research (AACR) 2023 Annual Meeting. In addition, the company presented new preclinical data in a poster titled “Preclinical development of ELU001 - a folate receptor alpha (FR?)-targeted C’Dot drug conjugate (CDC) for the treatment of brain metastases” (abstract #837).

View post:
Elucida Oncology Announces Positive Early Phase 1 Safety Data Along with Preclinical Data for the Treatment of Brain Metastases for ELU001, an...

Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice

View original post here:
Histogen Announces Online Publication in the Journal of Investigative Dermatology

VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB) (Xetra: ZSB) (the “Company”) announced today that it has closed an oversubscribed, non-brokered convertible debenture for gross proceeds of $1,563,600. The private placement consists of 1,563 Debenture units, (the “Debenture Units”) at a price of $1,000 per Debenture Unit.

Read the original:
Sirona Biochem Announces Close of Oversubscribed Debenture Financing

SAN DIEGO, April 20, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will participate in IBD Innovate: Product Development for Crohn’s & Colitis, an event hosted by the Crohn’s & Colitis Foundation to showcase innovative product development programs in inflammatory bowel disease (IBD), which will take place in New York City on April 26, 2023.

More:
Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference

Vallon’s board approves 1-for-30 reverse stock split

Visit link:
Vallon Pharmaceuticals Announces Stockholder Approval of Merger with GRI Bio, Inc. and Reverse Stock Split

Company Announcement

Read this article:
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen

GUANGZHOU, China, April 20, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 21, 2023 it filed its Annual Report on Form 20-F for the year ended December 31, 2022 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F is available for viewing on the SEC website at www.sec.gov and also on the Company’s website at http://ir.brbiotech.com. The Form 20-F has also been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

View original post here:
Burning Rock Publishes 2022 Annual Report on Form 20-F